MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Free Cash flow
-$12,797K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
Maturity of short-term investmen...
Accrued liabilities
Stock-based compensation expense
Others
Negative Cash Flow Breakdown
Purchase of short-term investmen...
Prepaid expenses and other curre...
Other non-current assets
Others
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Net loss
-22,371
-20,040
-23,577
-26,301
Depreciation expense
249
264
365
436
Stock-based compensation expense
4,187
4,254
4,525
6,418
Gain on sale of property and equipment
0
94
0
44
Non-cash operating lease expense
842
835
828
821
Net amortization (accretion) on short-term investments
118
-417
-282
-335
Loss on extinguishment of debt
-
-
-1,828
-
Prepaid expenses and other current assets
943
-1,724
209
-780
Other non-current assets
192
-323
0
0
Accounts payable
1,169
-118
-3
-897
Accrued liabilities
4,422
-6,474
-1,514
-2,031
Operating lease liabilities
-42
-320
-313
-598
Net cash used in operating activities
-12,797
-19,229
-17,788
-21,081
Purchase of short-term investments
17,316
64,900
85,085
52,563
Maturity of short-term investments
32,789
60,698
86,854
80,328
Purchase of property and equipment
0
0
0
0
Proceeds from sale of property, plant and equipment
17
102
-1
156
Net cash provided by investing activities
15,490
-4,100
1,768
27,921
Proceeds from issuances of common stock under benefit plans
0
74
0
72
Payment of debt
-
-
32,267
-
Proceeds from term loan, net of issuance costs
-
-
0
0
Net cash provided by financing activities
0
74
-32,267
72
Net (decrease) increase in cash and cash equivalents
2,693
-23,255
-48,287
6,912
Cash and cash equivalents and restricted cash at beginning of period
23,672
46,927
95,214
72,670
Cash, cash equivalents and restricted cash at end of period
26,365
-
-
-
Cash paid for interest
0
-
-
-
Cash and cash equivalents
24,883
-
-
-
Restricted cash
1,482
-
-
-
Total cash, cash equivalents, and restricted cash
26,365
23,672
46,927
95,214
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Maturity of short-term
investments
$32,789K
(-80.79%↓ Y/Y)
Proceeds from sale of
property, plant and...
$17K
Net cash provided by
investing activities
$15,490K
(-85.19%↓ Y/Y)
Canceled cashflow
$17,316K
Net (decrease)
increase in cash and cash...
$2,693K
(-82.77%↓ Y/Y)
Canceled cashflow
$12,797K
Purchase of short-term
investments
$17,316K
(-73.67%↓ Y/Y)
Accrued liabilities
$4,422K
(151.29%↑ Y/Y)
Stock-based compensation
expense
$4,187K
(-72.62%↓ Y/Y)
Accounts payable
$1,169K
(125.52%↑ Y/Y)
Non-cash operating lease
expense
$842K
(-48.28%↓ Y/Y)
Depreciation expense
$249K
(-72.18%↓ Y/Y)
Net cash used in
operating activities
-$12,797K
(85.70%↑ Y/Y)
Canceled cashflow
$10,869K
Net loss
-$22,371K
(77.51%↑ Y/Y)
Prepaid expenses and
other current assets
$943K
(147.87%↑ Y/Y)
Other non-current
assets
$192K
(546.51%↑ Y/Y)
Net amortization
(accretion) on short-term...
$118K
(103.53%↑ Y/Y)
Operating lease
liabilities
-$42K
(-220.00%↓ Y/Y)
Buy us a coffee
PLIANT THERAPEUTICS, INC. (PLRX)
PLIANT THERAPEUTICS, INC. (PLRX)